Rankings / Mood, Anxiety & Stress
Psilocybin
Mood, Anxiety & Stress · Classic psychedelic / 5-HT2A agonist
Tier B
What this is
Compass COMP360 Ph3 COMP005 (June 2025) met primary endpoint (-3.6 MADRS diff, p<0.001); COMP006 (Feb 2026) confirmed durability at 26 weeks; NDA rolling submission targeted Q4 2026 with possible approval late 2026/early 2027. Microdosing trials consistently fail to beat placebo despite anecdotes. Griffiths/Carhart-Harris foundational work.
Mechanism
Prodrug to psilocin; 5-HT2A receptor agonist (primary); promotes neuroplasticity via BDNF, dendritic spine formation; acute ego dissolution; default mode network modulation
Dose & route
1-5 g dried mushrooms (recreational); 25 mg synthetic psilocybin (clinical); 50-500 mg 'microdose'
Citations
- https://pubmed.ncbi.nlm.nih.gov/33146667/
- https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx
- https://pubmed.ncbi.nlm.nih.gov/34018053/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.